FDA approval for new once-daily HIV treatment Symfi™

The global pharmaceutical company Mylan N.V. (PA, USA) has received FDA approval for Symfi™ (efavirenz, lamivudine and tenofovir disoproxil fumarate) – a once-daily, single-tablet regimen, which is appropriate for HIV-1 infection in adult and pediatric patients weighing at least 40 kg.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment